The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Fully equipped labs with 75-member team set-up and made operational in <100 days
The combination will support clients in getting their end-to-end discovery and development programs delivered.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Revenue from operations up 26% to Rs. 768 crores
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Subscribe To Our Newsletter & Stay Updated
